High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
about
HPV and Cervical Cancer: Updates on an Established RelationshipRole of human papillomaviruses in carcinogenesisRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Role of the microbiome in non-gastrointestinal cancersPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVThe "HPV Discussion": Effective Use of Data to Deliver Recommendations to Patients Impacted by HPVSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusLessons learned from next-generation sequencing in head and neck cancerLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsSafety of human papillomavirus vaccines: a reviewConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesCapsomer vaccines protect mice from vaginal challenge with human papillomavirusModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong KongSafety of human papillomavirus vaccines: a review.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.Human Papillomavirus type distribution in invasive cervical cancer in UgandaWarts (genital)Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast SpainCost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing countryHuman papillomavirus vaccination in survivors of childhood cancer.Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women.DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities.Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.Cost-effectiveness of different human papillomavirus vaccines in SingaporeUnderstanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus.Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccinationEvaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.Integrating clinical, community, and policy perspectives on human papillomavirus vaccinationVaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
P2860
Q22305479-D5E261F7-CE5B-4B4E-8373-F5F4D672FA68Q22305628-7F28B8F1-2ABC-4241-B4FA-5643E27117EDQ24600011-E96F83B6-F3F8-41A1-8450-5D8233DD3F7BQ26747710-A902EFCE-555B-430F-A1A9-9F6F1D5F9B39Q26749285-9167EF00-9F40-46EC-B377-DE5197700CE0Q26783973-D817E951-A461-40E9-B487-77FD8C28C40DQ26798297-E05443CA-0868-4E8C-87AE-7923D03202ADQ26799574-01C1FA6B-6B75-4476-BA58-647AC755856DQ27009209-F4975128-79EC-45B1-8D84-B694379EA597Q27013018-E746DB2E-2A30-453D-AE7B-69A69E5EE816Q28082119-F89EDF43-603B-4F1C-A3D2-82DBEDA04320Q28246307-5DFE1905-EEB4-471E-B13D-02DE882CF1C8Q28743261-AC80F264-1E1A-4FD1-9A34-FD791754697BQ30573204-1C82D192-A435-4844-9F40-CDA1C2AF0FF7Q31131825-28D4995A-AC76-490E-89CA-1E9C4D669C24Q33162724-92977AE6-E37B-4190-9FFF-48CD164D4159Q33292779-9C257762-48EE-463E-B5CE-0AF1511D9E66Q33346465-4045652B-C52E-41F0-8089-981DA7497FB5Q33448263-FDD2CDE2-B775-4392-A9F5-87A9D4B19332Q33491832-DBAD8E92-5E28-493F-81DE-BAAED1B0ECDAQ33523171-FA65BFE2-2CC1-402F-A21B-A02E97F10503Q33568522-37FC5FE3-F301-44F3-A19C-6BC7C6803322Q33572460-5BFBFB28-CDD5-42B3-AA95-391A8FD38DA2Q33622107-8868B1BA-C5C9-451C-B22E-58D36390D285Q33665786-75F1DE91-8BB3-45F3-9E25-C1CBC8F008B0Q33696724-F3CFB30B-2B5B-446E-B54A-07C081194363Q33708098-CA40D75D-DACA-471F-800F-F82F49A2C272Q33723292-39B0BF8B-E4CF-4EBA-9175-74592879CB22Q33723312-E371DDEF-F465-4CCC-B210-5439C2DAE8ECQ33774640-86D54649-8088-408E-9F36-4CE80ACE4ABEQ33791312-4E9E7C1B-F04B-438E-9905-A656DFCE8AB9Q33858092-425DF81F-8F3E-4FDE-86A1-6DA1C169DB6EQ33859018-9A153D69-B6E3-42C7-A4CF-504984E40918Q33894441-2C411B06-80E8-48BB-B83C-00DA3C78710FQ34029941-5DD5D94D-0040-4540-B046-F312019522EEQ34033823-AAF3C155-F6BB-4767-B558-F21DEECEEF17Q34038946-15EC6A34-EE33-454C-A1FE-358846CE35CDQ34054427-0AC7DEA7-F739-4C18-A679-D900B03F689AQ34078572-8018ECDE-BF60-4264-9192-616A8BCDAC7BQ34078674-E93ABE5E-2F52-4016-94C1-68397CDF63AA
P2860
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
High sustained efficacy of a p ...... e through 5 years of follow-up
@ast
High sustained efficacy of a p ...... e through 5 years of follow-up
@en
type
label
High sustained efficacy of a p ...... e through 5 years of follow-up
@ast
High sustained efficacy of a p ...... e through 5 years of follow-up
@en
prefLabel
High sustained efficacy of a p ...... e through 5 years of follow-up
@ast
High sustained efficacy of a p ...... e through 5 years of follow-up
@en
P2093
P2860
P356
P1476
High sustained efficacy of a p ...... e through 5 years of follow-up
@en
P2093
A Andersson-Ellstrom
F J Taddeo
G Riis-Johannessen
G von Krogh
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603469
P407
P577
2006-11-21T00:00:00Z